Mathialagan Karthik, Tai Cheng-Hung, Sethi Samdish, Thomas Sumi, Loeser Caroline
Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.
Section of Gastroenterology, Department of Medicine, Yale-New Haven Health-Bridgeport Hospital, Bridgeport, CT.
ACG Case Rep J. 2023 Aug 14;10(8):e01128. doi: 10.14309/crj.0000000000001128. eCollection 2023 Aug.
Immune checkpoint inhibitors (ICIs) have been increasingly used in the treatment of several malignancies and may target cytotoxic T-lymphocyte-associated antigen-4, programmed cell death-1, and programmed cell death ligand 1, which work on maintaining peripheral immune tolerance. ICIs inhibit these ligands causing an immune-enhancing effect, leading to a wide spectrum of complications from mild mucositis to life-threatening pneumonitis or hepatitis. These complications are collectively called immune-related adverse events. Their prevalence has increased with a rise in ICI use, with rare manifestations being reported in popular literature. We present a case of hemorrhagic gastritis due to the anti-programmed cell death-1 antibody, pembrolizumab.
免疫检查点抑制剂（ICIs）已越来越多地用于多种恶性肿瘤的治疗，其可能靶向细胞毒性T淋巴细胞相关抗原4、程序性细胞死亡蛋白1和程序性细胞死亡配体1，这些蛋白作用于维持外周免疫耐受。ICIs抑制这些配体，产生免疫增强效应，导致从轻度粘膜炎到危及生命的肺炎或肝炎等广泛的并发症。这些并发症统称为免疫相关不良事件。随着ICIs使用的增加，其发生率也有所上升，大众文献中报道了一些罕见表现。我们报告一例因抗程序性细胞死亡蛋白1抗体帕博利珠单抗导致的出血性胃炎病例。
